27631520|t|Novel High-grade Endometrial Stromal Sarcoma: A Morphologic Mimicker of Myxoid Leiomyosarcoma
27631520|a|Endometrial stromal sarcomas (ESS) are often underpinned by recurrent chromosomal translocations resulting in the fusion of genes involved in epigenetic regulation. To date, only YWHAE-NUTM2 rearrangements are associated with distinctive high-grade morphology and aggressive clinical behavior. We identified 3 ESS morphologically mimicking myxoid leiomyosarcoma of the uterus and sought to describe their unique histopathologic features and identify genetic alterations using next-generation sequencing. All cases displayed predominantly spindled cells associated with abundant myxoid stroma and brisk mitotic activity. Tumors involved the endometrium and demonstrated tongue-like myometrial infiltration. All 3 were associated with an aggressive clinical course, including multisite bony metastases in 1 patient, progressive peritoneal disease after chemotherapy in another, and metastases to the lung and skin in the last patient. All 3 ESS were found to harbor ZC3H7B - BCOR gene fusions by targeted sequencing and fluorescence in situ hybridization. On the basis of the review of these cases, we find that ESS with ZC3H7B - BCOR fusion constitutes a novel type of high-grade ESS and shares significant morphologic overlap with myxoid leiomyosarcoma.
27631520	6	44	High-grade Endometrial Stromal Sarcoma	T191	C2239246
27631520	48	68	Morphologic Mimicker	T033	C0243095
27631520	72	93	Myxoid Leiomyosarcoma	T191	C0205816
27631520	94	122	Endometrial stromal sarcomas	T191	C0206630
27631520	124	127	ESS	T191	C0206630
27631520	164	190	chromosomal translocations	T049	C0040715
27631520	208	223	fusion of genes	T063	C0178648
27631520	236	257	epigenetic regulation	T043	C0007613
27631520	273	284	YWHAE-NUTM2	T028	C4287955
27631520	285	299	rearrangements	T045	C0017287
27631520	343	353	morphology	T080	C0332437
27631520	358	386	aggressive clinical behavior	T033	C0243095
27631520	404	407	ESS	T191	C0206630
27631520	408	433	morphologically mimicking	T033	C0243095
27631520	434	455	myxoid leiomyosarcoma	T191	C0205816
27631520	463	469	uterus	T023	C0042149
27631520	506	530	histopathologic features	T169	C0243140
27631520	544	563	genetic alterations	T045	C0026882
27631520	570	596	next-generation sequencing	T063	C2936625
27631520	632	646	spindled cells	T025	C0007634
27631520	672	678	myxoid	T080	C0205295
27631520	679	685	stroma	T023	C0927195
27631520	696	712	mitotic activity	T033	C1334779
27631520	714	720	Tumors	T191	C0027651
27631520	734	745	endometrium	T023	C0014180
27631520	775	785	myometrial	T029	C0521387
27631520	775	798	myometrial infiltration	T046	C0332448
27631520	830	856	aggressive clinical course	T033	C1332223
27631520	868	877	multisite	T082	C1254362
27631520	878	893	bony metastases	T191	C0027627
27631520	899	906	patient	T101	C0030705
27631520	908	919	progressive	T169	C0205329
27631520	920	938	peritoneal disease	T047	C0031142
27631520	945	957	chemotherapy	T061	C3665472
27631520	974	984	metastases	T191	C0027627
27631520	992	996	lung	T023	C0024109
27631520	1001	1005	skin	T022	C1123023
27631520	1018	1025	patient	T101	C0030705
27631520	1033	1036	ESS	T191	C0206630
27631520	1058	1064	ZC3H7B	T028	C1823919
27631520	1067	1071	BCOR	T028	C1427193
27631520	1072	1084	gene fusions	T063	C0178648
27631520	1088	1107	targeted sequencing	T059	C1294197
27631520	1112	1146	fluorescence in situ hybridization	T063	C0162789
27631520	1184	1189	cases	T169	C0868928
27631520	1204	1207	ESS	T191	C0206630
27631520	1213	1219	ZC3H7B	T028	C1823919
27631520	1222	1226	BCOR	T028	C1427193
27631520	1227	1233	fusion	T063	C0178648
27631520	1262	1276	high-grade ESS	T191	C2239246
27631520	1300	1319	morphologic overlap	T033	C1513488
27631520	1325	1346	myxoid leiomyosarcoma	T191	C0205816